Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CytomX Therapeutics (CTMX) Net Income towards Common Stockholders (2016 - 2025)

CytomX Therapeutics (CTMX) has disclosed Net Income towards Common Stockholders for 12 consecutive years, with -$14.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Net Income towards Common Stockholders fell 348.06% year-over-year to -$14.2 million, compared with a TTM value of $28.0 million through Sep 2025, up 102.57%, and an annual FY2024 reading of $31.9 million, up 5700.88% over the prior year.
  • Net Income towards Common Stockholders was -$14.2 million for Q3 2025 at CytomX Therapeutics, down from -$154000.0 in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at $23.5 million in Q1 2025 and bottomed at -$34.8 million in Q4 2021.
  • Average Net Income towards Common Stockholders over 5 years is -$8.4 million, with a median of -$6.5 million recorded in 2024.
  • Peak annual rise in Net Income towards Common Stockholders hit 2155.08% in 2024, while the deepest fall reached 501.01% in 2024.
  • Year by year, Net Income towards Common Stockholders stood at -$34.8 million in 2021, then surged by 74.8% to -$8.8 million in 2022, then soared by 109.54% to $837000.0 in 2023, then soared by 2155.08% to $18.9 million in 2024, then tumbled by 175.39% to -$14.2 million in 2025.
  • Business Quant data shows Net Income towards Common Stockholders for CTMX at -$14.2 million in Q3 2025, -$154000.0 in Q2 2025, and $23.5 million in Q1 2025.